Smoking Cessation — Efficacy and Cost of State Quitline Policies
Citation(s)
Aickin M, Gensler H Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods. Am J Public Health. 1996 May;86(5):726-8.
Curry SJ, Grothaus LC, McAfee T, Pabiniak C Use and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organization. N Engl J Med. 1998 Sep 3;339(10):673-9.
Curry SJ, McBride C, Grothaus LC, Louie D, Wagner EH A randomized trial of self-help materials, personalized feedback, and telephone counseling with nonvolunteer smokers. J Consult Clin Psychol. 1995 Dec;63(6):1005-14.
Erickson P, Wilson R, Shannon I Years of Healthy Life. Statistical Notes. Centers for Disease Control and Prevention, National Center for Health Statistics 1995; 7:1-14.
Fiscella K, Franks P Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. JAMA. 1996 Apr 24;275(16):1247-51.
Korberly B An open label multicenter trial to evaluate and compare the efficacy of Nicotrol 15mg as part of an OTC intervention package or as a prescription as an aid in smoking cessation. Presented at the meeting of the Society for Research on Nicotine and Tobacco, San Diego, CA, 1999.
Lichtenstein E, Brown RA Current trends in the modification of cigarette dependence. In Bellack AS, Hersen M, Kazdin AE (eds.). International Handbook of Behavioral Modification and Therapy. New York: Plenum Press, 1982, 575-611.
Lippiatt BC Measuring medical cost and life expectancy impacts of changes in cigarette sales. Prev Med. 1990 Sep;19(5):515-32.
Lipscomb J, Weinstein MC, Torrance GW Time preference. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in Health and Medicine, Ch. 7.. New York: Oxford University Press, 1996.
Little RJA, Rubin DB Statistical analysis with missing data. New York: John Wiley & Sons, 1987.
Manning WG, Fryback DG, Weinstein MC Reflecting uncertainty in cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in Health and Medicine, Ch. 8. New York: Oxford University Press, 1996
Marlatt GA and Gordon JR (Eds) Relapse Prevenion: Maintenance strategies in the treatment of addictive behaviors. New York: Guilford Press, 1985.
Miller WR, Rollnick S Motivational Interviewing: Preparing People to Change Addictive Behavior. New York: The Guilford Press, 1991.
O'Brien BJ, Drummond MF, Labelle RJ, Willan A In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care. 1994 Feb;32(2):150-63.
Rollnick S, Heather N, Bell A Negotiating behaviour change in medical settings: The development of brief motivational interviewing. Journal of Mental Health 1992; 1:25-37.
Shiffman S Efficacy of nicotine gum and patch under OTC and real-world prescription conditions. Presented at the meeting of the Society for Research on Nicotine and Tobacco, San Diego, CA, 1999.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
